Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAN-NEURO-01
- Development stage
- Preclinical
- Lead developer
- Kantify
- Modality
- Small Molecules
01
Overview
KAN-NEURO-01 is a first-in-class small molecule modulator of the ubiquitination pathway currently in preclinical development for the treatment of Autism Spectrum Disorder (ASD). Discovered using Kantify's Sapian™ AI platform, the drug is being developed in collaboration with the CNRS-IPMC (Institut de Pharmacologie Moléculaire et Cellulaire). It aims to address the underlying biological mechanisms of ASD by targeting specific components of the protein degradation machinery, although the exact molecular target within the ubiquitination system has not been publicly disclosed. The program is currently undergoing preclinical validation.
Beyond the preview
Go deeper on KAN-NEURO-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAN-NEURO-01.